Table 1.

Somatic functional inactivating CTNNA1 mutations and breast cancer phenotype

Sample ID	CTNNA1 status			Diagnosis		CDH1
	AA change	Copy #	mRNA	Initial	Revised
TCGA‐EW‐A1OV‐01	R129*	ShallowDel	0%	IDC‐NOS	Mixed IDL	WT
MB‐3600	X101_s	ShallowDel	1%	IDC‐NOS	IDC‐NOS†	WT
TCGA‐AC‐A3TM‐01	R54C	Diploid	21%	ILC	Ducto‐lobular	MUT
MB‐4667	Q887*	Diploid	27%	ILC	PILC	MUT‡
TCGA‐A2‐A1FX‐01	X634_s	Gain	37%	IDC‐NOS	Mixed IDL	WT
MB‐7157	K733*	Diploid	40%	IDC‐NOS	IDC‐NOS	WT
MB‐5431	D904A	ShallowDel	61%	IDC‐NOS	IDC‐NOS	WT
TCGA‐AN‐A046‐01	R98*	Diploid	64%	IDC‐NOS	IDC‐NOS	WT
MB‐6107	R126Q	Diploid	73%	ILC	ILC	MUT
MB‐5455	R300C	Diploid	78%	Mixed IDL	Mixed IDL	WT
MB‐5584	R586C	Diploid	78%	ND	ND	WT
TCGA‐BH‐A18U‐01	S558 L	Gain	81%	IDC‐NOS	IDC‐NOS	WT
MB‐6211	A224T	Gain	85%	IDC‐NOS	Ducto‐lobular	WT
TCGA‐A8‐A0A6‐01	V688G	Diploid	87%	ILC	ILC	MUT
MB‐0653	D114H	Diploid	91%	ILC (solid)	ILC (solid)	MUT
MB‐4855	A885V	Gain	92%	IDC‐NOS	IDC‐NOS	WT
MB‐5284	P462L	Diploid	92%	Mixed IDL	IDC‐NOS	WT
TCGA‐AN‐A0XW‐01	E432Q	Diploid	92%	IDC‐NOS	IDC‐NOS	WT
MTS‐T0697	E406*	ShallowDel	ND	IDC‐NOS	IDC‐NOS	WT

AA = amino acid; IDC‐NOS = invasive ductal carcinoma, not otherwise specified; ILC = invasive lobular carcinoma; PILC = pleomorphic ILC; IDL = invasive ductal and lobular; ND = no data; WT = wild type; MUT = mutant; _s = splice;

Mutations in bold are potentially pathogenic.

^†Contains signet ring cells;

^‡40% mRNA expression.